Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Botulinum toxin type A in pregnancy

Michael Tan, Eunji Kim, Gideon Koren and Pina Bozzo
Canadian Family Physician November 2013, 59 (11) 1183-1184;
Michael Tan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eunji Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gideon Koren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pina Bozzo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Question My patient received 62 units of botulinum toxin type A (BTX-A) for facial lines. Two weeks later, she found out that she was pregnant. Will this cause any harm to her fetus?

Answer Botulinum toxin is not expected to be present in systemic circulation following proper intramuscular or intradermal injection. Moreover, BTX-A, which has a high molecular weight, does not appear to cross the placenta. From the 38 pregnancies reported in the literature, including women who had botulism poisoning during pregnancy, exposure to BTX-A does not appear to increase the risk of adverse outcome in the fetus.

Botulinum toxin type A (BTX-A) is a purified neurotoxin from the bacterium Clostridium botulinum. It has numerous medical applications such as treatment of cervical dystonia, focal spasticity, strabismus, achalasia, blepharospasm, hyperhidrosis, migraine, and tension headache.1 It has also become popular among dermatologists and plastic surgeons for its cosmetic indications to temporarily paralyze facial muscles and diminish wrinkles in the skin.2 With more women delaying pregnancy until later in life, inadvertent exposure of pregnant women to BTX-A is likely to occur at a greater frequency.

Botulinum toxin is a large protein with a high molecular weight (150 kD).2 When injected intramuscularly in recommended doses, BTX-A is not expected to enter systemic circulation.2 Therefore, BTX-A is unlikely to be present at the maternal-fetal interface.

In rabbits, botulinum toxin was not detectable in the placenta or in the fetuses when given intravenously in highly lethal doses.3 However, fetal malformations and abortions were reported in rabbits with daily injections of BTX-A (doses of 0.125 U/kg and 0.5 U/kg daily, and 2 U/kg, 4 U/kg, and 6 U/kg).2 Similar adverse fetal outcomes were not found in pregnant mice.2

Information about exposure to botulinum toxin in human pregnancy is limited to case reports and a survey.4–18 Seven cases of women with botulism poisoning in either their second or third trimester have been reported.4–10 No evidence of birth defects or infantile botulism in the neonates was noted in any case. In one case, when maternal paralysis was severe, fetal movements were the only visible movements in her body.6 In 2 of the above cases, infant serum was taken and no botulinum toxin was detected.4,10 An additional 28 pregnancies with exposure to BTX-A therapy (at least 18 of 28 had first-trimester exposure) reported 25 normal live pregnancies, 1 therapeutic abortion, and 2 spontaneous abortions.11–16 Both women who had spontaneous abortions had histories of spontaneous abortions. There are also 3 reports of first-trimester use of BTX-A for cosmetic indications.17,18 Two healthy babies were delivered, and no details were provided for the third case.

With proper administration of BTX-A, it is not expected to enter systemic circulation. Therefore, based on its local action and on the existing data, administering BTX-A to a pregnant woman is not expected to cause any fetal harm. However, until more data are available, benefits and potential risks to both the mother and the infant should be considered when recommending BTX-A injection to a pregnant patient.

Notes

Motherisk

Motherisk questions are prepared by the Motherisk Team at the Hospital for Sick Children in Toronto, Ont. Dr Tan and Ms Kim are members, Dr Koren is Director, and Ms Bozzo is Assistant Director of the Motherisk Program. Dr Koren is supported by the Research Leadership for Better Pharmacotherapy during Pregnancy and Lactation. He holds the Ivey Chair in Molecular Toxicology in the Department of Medicine at the University of Western Ontario in London.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in women who are pregnant or breastfeeding? We invite you to submit them to the Motherisk Program by fax at 416 813-7562; they will be addressed in future Motherisk Updates. Published Motherisk Updates are available on the Canadian Family Physician website (www.cfp.ca) and also on the Motherisk website (www.motherisk.org).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    Botox [product monograph]. Irvine, CA: Allergan Inc; 2011.
  2. 2.↵
    Botox Cosmetic [product monograph]. Irvine, CA: Allergan Inc; 2011.
  3. 3.↵
    1. Hildebrand GJ,
    2. Lamanna C,
    3. Heckly RJ
    . Distribution and particle size of type A botulinum toxin in body fluids of intravenously injected rabbits. Proc Soc Exp Biol Med 1961;107(284):284-9.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. St Clair EH,
    2. DiLiberti JH,
    3. O’Brien ML
    . Observations of an infant born to a mother with botulism [Letter]. J Pediatr 1975;87(4):658.
    OpenUrlCrossRefPubMed
  5. 5.
    1. Centers for Disease Control and Prevention
    . Wound botulism—California, 1995. MMWR Morb Mortal Wkly Rep 1995;44(48):889-92.
    OpenUrlPubMed
  6. 6.↵
    1. Polo JM,
    2. Martin J,
    3. Berciano J
    . Botulism and pregnancy. Lancet 1996;348(9021):195.
    OpenUrlPubMed
  7. 7.
    1. Robin L,
    2. Herman D,
    3. Redett R
    . Botulism in a pregnant woman. N Engl J Med 1996;335(11):823-4.
    OpenUrlCrossRefPubMed
  8. 8.
    1. Morrison GA,
    2. Lang C,
    3. Huda S
    . Botulism in a pregnant intravenous drug abuser. Anaesthesia 2006;61(1):57-60.
    OpenUrlPubMed
  9. 9.
    1. Magri K,
    2. Bresson V,
    3. Barbier C
    . Botulisme et grossesse. J Gynecol Obstet Biol Reprod (Paris) 2006;35(6):624-6.
    OpenUrlPubMed
  10. 10.↵
    1. Centers for Disease Control and Prevention
    . Type A botulism—Oregon. MMWR 1973;22(26):218-23.
    OpenUrl
  11. 11.↵
    1. Newman WJ,
    2. Davis TL,
    3. Padaliya BB,
    4. Covington CD,
    5. Gill CE,
    6. Abramovitch AI,
    7. et al
    . Botulinum toxin type A therapy during pregnancy. Mov Disord 2004;19(11):1384-5.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Bodkin CL,
    2. Maurer KB,
    3. Wszolek ZK
    . Botulinum toxin type A therapy during pregnancy. Mov Disord 2005;20(8):1081-2.
    OpenUrlCrossRefPubMed
  13. 13.
    1. Morgan JC,
    2. Iyer SS,
    3. Moser ET,
    4. Singer C,
    5. Sethi KD
    . Botulism toxin A during pregnancy: a survey of treating physicians. J Neurol Neurosurg Psychiatry 2006;77(1):117-9.
    OpenUrlAbstract/FREE Full Text
  14. 14.
    1. Wataganara T,
    2. Leelakusolvong S,
    3. Sunsaneevithayakul P,
    4. Vantanasiri C
    . Treatment of severe achalasia during pregnancy with esophagoscopic injection of botulinum toxin A: a case report. J Perinatol 2009;29(9):637-9.
    OpenUrlPubMed
  15. 15.
    1. Li Yim JF,
    2. Weir CR
    . Botulinum toxin and pregnancy—a cautionary tale. Strabismus 2010;18(2):65-6.
    OpenUrlPubMed
  16. 16.↵
    1. Aranda MA,
    2. Herranz A,
    3. del Val J,
    4. Bellido S,
    5. García-Ruiz P
    . Botulinum toxin A during pregnancy, still a debate. Eur J Neurol 2012;19(8):e81-2.
    OpenUrlPubMed
  17. 17.↵
    1. De Oliveira Monteiro E
    . Botulinum toxin and pregnancy. Skinmed 2006;5(6):308.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Kuczkowski KM
    . Anesthetic implications of botulinum toxin type A (Botox) injections for the treatment of ‘the aging face’ in the parturient. Acta Anaesthesiol Scand 2007;51(4):515-6.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 59 (11)
Canadian Family Physician
Vol. 59, Issue 11
1 Nov 2013
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Botulinum toxin type A in pregnancy
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Botulinum toxin type A in pregnancy
Michael Tan, Eunji Kim, Gideon Koren, Pina Bozzo
Canadian Family Physician Nov 2013, 59 (11) 1183-1184;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Botulinum toxin type A in pregnancy
Michael Tan, Eunji Kim, Gideon Koren, Pina Bozzo
Canadian Family Physician Nov 2013, 59 (11) 1183-1184;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Motherisk Update

  • Hepatitis A infection during pregnancy
  • Fluconazole use during breastfeeding
  • Is it safe to breastfeed while taking methylphenidate?
Show more Motherisk Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2021 by The College of Family Physicians of Canada

Powered by HighWire